|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
195,811,000 |
Market
Cap: |
1.32(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.08 - $6.74 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing plasma-derived biologics for the treatment of immunodeficient patients at risk for infectious diseases. Co.'s products include: BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), an IVIG product indicated for the treatment of PI; and Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
155,000 |
191,958 |
Total Buy Value |
$0 |
$0 |
$579,644 |
$685,344 |
Total People Bought |
0 |
0 |
2 |
4 |
Total Buy Transactions |
0 |
0 |
2 |
5 |
Total Shares Sold |
1,500,000 |
1,500,000 |
4,083,538 |
4,083,538 |
Total Sell Value |
$9,143,159 |
$9,143,159 |
$19,811,348 |
$19,811,348 |
Total People Sold |
1 |
1 |
4 |
4 |
Total Sell Transactions |
5 |
5 |
11 |
11 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lenz Brian |
EVP, CFO |
|
2020-08-11 |
4 |
B |
$2.97 |
$11,860 |
D/D |
4,000 |
76,142 |
2.74 |
-23% |
|
Grossman Adam S |
President and CEO |
|
2020-08-11 |
4 |
B |
$2.97 |
$2,970 |
D/D |
1,000 |
172,098 |
2.73 |
-23% |
|
Grossman Adam S |
President and CEO |
|
2020-08-10 |
4 |
B |
$3.04 |
$15,290 |
D/D |
5,000 |
171,098 |
2.81 |
-26% |
|
Mond James |
EVP, CSO and CMO |
|
2020-08-10 |
4 |
B |
$2.88 |
$20,150 |
D/D |
7,000 |
69,174 |
2.74 |
-26% |
|
Edelman Joseph |
10% Owner |
|
2020-03-19 |
4 |
B |
$2.10 |
$1,050,000 |
I/I |
500,000 |
16,584,802 |
1.5 |
35% |
|
Elms Steve |
Director |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
Grossman Jerrold B |
Director |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
140,364 |
|
- |
|
Lenz Brian |
EVP, CFO |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
72,142 |
|
- |
|
Grossman Adam S |
President and CEO |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
166,098 |
|
- |
|
Richman Eric I |
Director |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
44,030 |
|
- |
|
Fong Bryant |
Director |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
Guiheen Lawrence P. |
Director |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
77,500 |
|
- |
|
Mond James |
EVP, CSO and CMO |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
62,174 |
|
- |
|
Goldstein Dov A Md |
Director |
|
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
Lenz Brian |
EVP, CFO |
|
2020-02-11 |
4 |
B |
$3.50 |
$24,997 |
D/D |
7,142 |
32,142 |
2.74 |
-18% |
|
Grossman Adam S |
President and CEO |
|
2020-02-11 |
4 |
B |
$3.50 |
$200,001 |
I/I |
57,143 |
878,444 |
2.66 |
-18% |
|
Grossman Adam S |
President and CEO |
|
2020-02-11 |
4 |
B |
$3.50 |
$99,999 |
D/D |
28,571 |
66,098 |
2.81 |
-18% |
|
Guiheen Lawrence P. |
Director |
|
2020-02-11 |
4 |
B |
$3.50 |
$70,000 |
D/D |
20,000 |
70,000 |
2.39 |
-18% |
|
Grossman Jerrold B |
Director |
|
2020-02-11 |
4 |
B |
$3.50 |
$80,000 |
I/I |
22,857 |
22,857 |
2.1 |
-18% |
|
Grossman Jerrold B |
Director |
|
2020-02-11 |
4 |
B |
$3.50 |
$80,000 |
D/D |
22,857 |
132,864 |
2.39 |
-18% |
|
Mond James |
CSO and CMO |
|
2020-02-11 |
4 |
B |
$3.50 |
$14,998 |
D/D |
4,285 |
22,174 |
2.74 |
-18% |
|
Edelman Joseph |
10% Owner |
|
2020-02-11 |
4 |
B |
$3.50 |
$15,972,950 |
I/I |
4,563,700 |
16,084,802 |
1.5 |
-18% |
|
Biotest Divestiture Trust |
10% Owner |
|
2019-06-06 |
4 |
S |
$3.75 |
$21,802,328 |
D/D |
(5,813,954) |
4,295,580 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2019-05-21 |
4 |
B |
$4.00 |
$16,000,000 |
I/I |
4,000,000 |
11,521,102 |
1.5 |
- |
|
Grossman Jerrold B |
Director |
|
2019-05-17 |
4 |
B |
$4.00 |
$48,000 |
D/D |
12,000 |
110,007 |
2.39 |
- |
|
222 Records found
|
|
Page 5 of 9 |
|
|